ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-01
REPORT DATE
29-Oct-2024

Gender: Female | Birth year: 1975 | WHO: 1

Tumor: Lung - Adenocarcinoma | Lesions: Brain, CNS, Lung | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history 1/2023-9/2024 Osimertinib

Relevant other oncological history None

Previous primary tumor Skin (neck) squamous cell carcinoma (diagnosed 1/2022, last treatment 1/2022,

considered non-active)

Relevant non-oncological history 9/2024 Bacterial pneumonia

2022 Rheumatoid arthritis

Recent molecular results

Hartwig WGS (01-Sep-2024)

Biopsy location Lung (purity 50%)

Molecular tissue of origin prediction Lung: Non-small cell: LUAD (98%)

Tumor mutational load / burden TML high (160) / TMB high (14)

Microsatellite (in)stability Stable

HR status Proficient (0)

High driver mutations EGFR L858R, EGFR C797S, KRAS G12D

Amplified genes

Deleted genes

TP53

Homozygously disrupted genes

None

Gene fusions

MET_MET

Virus detection

None

Potentially actionable events with medium/low driver:

None

IHC results PD-L1: Score > 50%

Example trials that are open and potentially eligible (2 cohorts from 2 trials)

Trial	Cohort	Molecular	Warnings
METC 04 TEDR1	Lung cancer C797S cohort	EGFR C797S	None
METC 02 KAYRAS	Dose expansion - monotherapy - NSCLC	KRAS G12D	Variant(s) KRAS G12D in KRAS but subclonal likelihood of > 50%

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-01
REPORT DATE
29-Oct-2024

Trial Matching Summary

Example trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

Example trials and cohorts that are open but considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Dose expansion - monotherapy - Colorectum	KRAS G12D	Tumor type
METC 03 NO-SEE797ES	Dose escalation - monotherapy		C797S detected in EGFR

Open cohorts with no slots available are shown in grey.